Corporate - Media & Press - Press Release
Dr. Mark Schena et al. publish Nature Medicine review.
Sunnyvale, CA, January 29, 2003 – On January 1st the prestigious scientific journal Nature Medicine, part of the Nature Publishing Group, published a microarray review by Dr. Robin Stears. Co-authors included company founder and Executive Vice President Todd Martinsky and Visiting Scholar Dr. Mark Schena.
The review article “Trends in Microarray Analysis” was featured in the Special Focus: Technology Trends portion of the January 2003 edition of Nature Medicine (Nature Medicine 9: 140-145, 2003). Assistant editor Dr. Diane Gershon organized the Special Focus section and guided its content.
“The positive reviews from the referees seemed to vindicate our impartial treatment of the field”, Dr. Schena added. “I think this speaks to our leadership role in the field, our integrity as a commercial organization, and our commitment to advancing science first and foremost”, Martinsky concluded.
Click here to download “Trends in Microarray Analysis”.
TeleChem International is a privately owned high-tech company located in the heart of California’s Silicon Valley. Our products and services are provided by three corporate divisions: ArrayIt® Life Sciences Division, Chemicals Division, and a Diagnostics Division. The ArrayIt® Life Sciences Division offers a complete microarray technology platform that empowers >10,000 laboratories to use microarrays for human genome exploration, basic research, drug discovery, and myriad life sciences applications. Nearly every major research institution uses our patented microarray manufacturing technology (U.S. 6,101,946) and supporting products and services. The Chemicals Division provides import and export services and government contract manufacturing in the area of industrial chemicals for plastics, fire control, water treatment, agriculture, industrial and institutional compounding, and green energy. The Diagnostics Division holds key patents in the United States (6,913,879), Singapore (94899), New Zealand (523560), and other countries for its revolutionary “multi-patient” genotyping technology, which allows as many as 100,000 patients to be tested on a single microarray. Arrayit Diagnostics enables genotyping and disease diagnostics by providing testing kits, services, and technology transfer opportunities for disease screening and testing organizations.
Copyright 1993-2018 Arrayit Corporation. All rights reserved.